Leading the Charge: How haematology Drives Cancer Discocery and Treatment Innovation

Haematology and blood cancer research have historically paved the way for modern oncology, beginning with the discovery of the first cancer biomarker-the Bence Jones protein representing free light chains in urine-and its association with multiple myeloma in 1847. This foundational role continued with the first use of intravenous chemotherapy, marked by the administration of nitrogen mustard in 1942, which proved that systemic chemical agents could successfully target and shrink lymphoma. Over time, continuous innovation aided by technological advances, including genome sequencing, has deeply improved our understanding of the biological processes involved in the pathogenesis of cancer and resulted in major changes to the World Health Organization classification. A monumental breakthrough followed in transforming chronic myeloid leukaemia, which is driven by the t (9;22) Philadelphia chromosome and its BCR-ABL1 tyrosine kinase, culminating in clinical trials starting in 1998 and the landmark FDA approval of the first targeted tyrosine kinase inhibitor, imatinib, in 2001. This pinnacle in precision medicine transformed a lethal disease before 2000 into a chronic illness, with a 10-year relative survival rate of 92%. Today, haematology remains a leading field in medicine, highlighted by milestones such as the first clinical use of a targeted antibody against cancer and the modern application of advanced treatments including bispecific T-cell engagers and chimeric antigen receptor T-cell therapies. There is little doubt that the future of solid cancer therapies will be based on these innovations.